SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.58+0.9%Dec 10 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Shawn Donahue who wrote (5326)1/4/2002 11:23:21 AM
From: Biomaven  Read Replies (3) of 52153
 
Shawn,

On IMCL, the short answer is to look at what BMY paid for their share of the drug.

Well my previous response was both short and wrong. I guess that's better than long and wrong. <g>

At this point I'm hearing some views that say that proving to the FDA that the patients in the trial were in fact refractory is hard. I think the stock is best avoided until we hear a report on their meeting with the FDA.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News